

Ebixa

[View the current Ebixa Page on BioPortfolio.com](http://www.bioportfolio.com)

(<http://www.bioportfolio.com/biocorporate/22286-Ebixa.html>)

Contact Details:

**H. Lundbeck A/S Ottilavej 9
Copenhagen
Valby
DK 2500
Denmark**

Tel: 45 36 30 13 11
Fax: 45 36 30 19 40
Email: information@lundbeck.com

Ebixa is an effective, safe and well tolerated therapy, that helps overcome the everyday challenges in Alzheimer's disease, easing the lives of both patients and their carers. Ebixa is indicated for the treatment of moderate to severe Alzheimer's disease. Ebixa is a specific, uncompetitive NMDA-receptor antagonist, with a novel mechanism of action that targets the glutamatergic signalling in the brain.

Press Releases on Ebixa:

[Diagnosis and Drug](#)

[Treatment of](#)

[Alzheimer's Disease in](#)

[China is Low and Will Remain](#)

[Low Through 2012](#)

3rd December, 2008

Decision Resources

WALTHAM, Mass., Dec. 3 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that the diagnosis

[An introduction to the key CNS Disorders](#)

1st January, 1970

Dailyupdates

An introduction to the key CNS Disorders Alzheimer's Disease: Over the last 3 years, the value of the Alzheimer's disease market has grown by an average of 19% per year. Growth has been

[The CNS Market Outlook to 2009](#)

1st January, 1970

Datamonitor

The CNS Market Outlook to 2009 The management report 'The CNS Market Outlook to 2009' provides in-depth analysis of the current growth opportunities, threats, leading players and their future

BioNews Results for Ebixa



- [Institute for Quality and Efficiency in Health Care: Benefit of memantine in the treatment of Alzheimer's disease not proven](#)
NewsRX: Nov 14 2009 5:14AM Matching: ebixa
- [Lundbeck posts steady set of financials for third quarter](#)
Pharma Times: Nov 5 2009 12:53AM Matching: ebixa
- [Third quarter 2009 report - Lundbeck records 20% growth, driven by Lundbeck Inc. and key products](#)
Therapeutics Daily: Nov 3 2009 11:22AM Matching: ebixa
- [No scientific proof that patients with Alzheimer's disease benefit from drugs containing the agent memantine](#)
News-Medical.Net: Oct 29 2009 5:33AM Matching: ebixa
- [Benefit Of Memantine In The Treatment Of Alzheimer's Disease Not Proven](#)
Red Orbit: Oct 28 2009 11:47PM Matching: ebixa
- [Benefit Of Memantine In The Treatment Of Alzheimer's Disease Not Proven](#)
Science Daily: Oct 28 2009 11:41PM Matching: ebixa
- [Benefit of memantine in the treatment of Alzheimer's disease not proven](#)
EurekAlert!: Oct 28 2009 3:26PM Matching: ebixa
- [Drug firm defends Nobel winner ad](#)
The Standard: Oct 21 2009 11:08PM Matching: ebixa

BioCorporate Profiles - upgrade to a full profile

BioPortfolio's BioCorporate full profiles offers your organization the opportunity to increase internet traffic to your corporate web site and enhance awareness of your business, technology, products and services. BioCorporate profiles are dynamic and are updated weekly with new information sourced from core information resources: publications, clinical trials, patents and global news.

Why you should upgrade your BioPortfolio BioCorporate profile:

- the ability to amend and add information on products and services to your profile using a membership username and password
- the option to add a corporate logo
- the creation of high value URL links back to your organization's website which will improve search engine ranking - resulting in increased site traffic

- the option have your press releases published on BioPortfolio and distributed via our BioNewsCast service
- an enhanced BioCorporate profile will also improve your exposure on BioPortfolio's related service InDepth and GeneDB

The annual cost is \$995.00 for established organizations and \$495.00 for organizations less than 12 months old.

Resources from the [NCBI](#) used in this document, [NCBI's standard disclaimer applies](#).

Nothing in this document should be used in place of personal medical advice from your own qualified medical practitioner. See BioPortfolio.com [User Agreement](#)

Send comments and feedback to:

Peter Barfoot Managing Director, BioPortfolio Ltd.

UK Tel: (+44) 1300 321501

USA Voicemail and Fax: (+1) 415 680 2472

[Peter Barfoot peter.barfoot@bioportfolio.com](mailto:peter.barfoot@bioportfolio.com)

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Stafford House, 10 Prince of Wales Road, Dorchester, Dorset, DT1 1PW, UK. No.3312883 VAT No. GB 744 6483 10

Copyright 1997-2009 - BioPortfolio Limited.

